BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24590359)

  • 1. Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era.
    Devaki P; Wong RJ; Marupakula V; Nangia S; Nguyen L; Ditah IC; Ehrinpreis MN; Nguyen MH
    Cancer; 2014 Jun; 120(11):1725-32. PubMed ID: 24590359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score.
    Wong RJ; Devaki P; Nguyen L; Cheung R; Cho-Phan C; Nguyen MH
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1534-40.e1. PubMed ID: 24361414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
    Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
    Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry.
    Wong RJ; Devaki P; Nguyen L; Cheung R; Nguyen MH
    Liver Transpl; 2014 May; 20(5):528-35. PubMed ID: 24415542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.
    Zavaglia C; De Carlis L; Alberti AB; Minola E; Belli LS; Slim AO; Airoldi A; Giacomoni A; Rondinara G; Tinelli C; Forti D; Pinzello G
    Am J Gastroenterol; 2005 Dec; 100(12):2708-16. PubMed ID: 16393224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
    Mazzaferro V; Llovet JM; Miceli R; Bhoori S; Schiavo M; Mariani L; Camerini T; Roayaie S; Schwartz ME; Grazi GL; Adam R; Neuhaus P; Salizzoni M; Bruix J; Forner A; De Carlis L; Cillo U; Burroughs AK; Troisi R; Rossi M; Gerunda GE; Lerut J; Belghiti J; Boin I; Gugenheim J; Rochling F; Van Hoek B; Majno P;
    Lancet Oncol; 2009 Jan; 10(1):35-43. PubMed ID: 19058754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score.
    Vitale A; Huo TL; Cucchetti A; Lee YH; Volk M; Frigo AC; Cescon M; Tuci F; Pinna AD; Cillo U
    Ann Surg Oncol; 2015; 22(6):1901-7. PubMed ID: 25234023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma.
    Roma J; Balbi E; Pacheco-Moreira L; Zyngier I; Araujo A; Agoglia L; Steinbruck K; Velaverde LG; Martinho JM
    Transplant Proc; 2012 Oct; 44(8):2423-7. PubMed ID: 23026611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
    Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
    J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
    Taniguchi M
    Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.
    Duffy JP; Vardanian A; Benjamin E; Watson M; Farmer DG; Ghobrial RM; Lipshutz G; Yersiz H; Lu DS; Lassman C; Tong MJ; Hiatt JR; Busuttil RW
    Ann Surg; 2007 Sep; 246(3):502-9; discussion 509-11. PubMed ID: 17717454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
    Ioannou GN; Perkins JD; Carithers RL
    Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002.
    Siegel AB; McBride RB; El-Serag HB; Hershman DL; Brown RS; Renz JF; Emond J; Neugut AI
    Am J Gastroenterol; 2008 Jan; 103(1):120-7. PubMed ID: 18005365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era.
    Levi DM; Tzakis AG; Martin P; Nishida S; Island E; Moon J; Selvaggi G; Tekin A; Madrazo BL; Narayanan G; Garcia MT; Feun LG; Tryphonopoulos P; Skartsis N; Livingstone AS
    J Am Coll Surg; 2010 May; 210(5):727-34, 735-6. PubMed ID: 20421039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for hepatocellular carcinoma within Milan Criteria in patients with Model for End-Stage Liver Disease score below 15: the impact of the etiology of cirrhosis on long-term survival.
    Tandoi F; Ponte E; Saffioti MC; Patrono D; Mirabella S; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2013 Sep; 45(7):2711-4. PubMed ID: 24034029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.